Here are five things to know:
• The stock has a 1 (strong buy) rating from Zacks Investment
• 12-month consensus target prices is $21
• Earnings per share are expected at $0.33 for the quarter
• K2M traded down 2.38 percent on Monday
• Trading volume is at 142,914
At the beginning of January, Piper Jaffray began coverage on K2M shares and set an “overweight” rating at $25 price target.
More articles on orthopedic devices:
Spine device company stock report: 5 key companies—Feb. 26
Globus Medical acquires device manufacturer—5 key notes
Invuity raises $20M in financing round
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
